CX Interviews
Key take-aways from the CX 2019 Highlight Session on Paclitaxel: The Last Word
Elena Ladich (Hollywood, USA) and Roger Greenhalgh (London, UK) discuss the current uncertainty surrounding the use of paclitaxel devices and the need for individual patient-level data analyses going forward to better understand the mortality [...]
CX 2019: Stroke following cardiac surgery is a “wake-up call”; safety of carotid stenting debate
In the Acute Stroke Challenges session on Monday, Nick Hopkins talks to CX Live about the “significant increase” of incidents of stroke following cardiac surgery which is “much more common than previously thought”. Ross [...]
CX Special Session will discuss the use of paclitaxel devices
CX Executive Board Members Gunnar Tepe and Thomas Zeller introduce the CX Special Session which aims to give the last word on paclitaxel and work with the vascular community to find the way forward. [...]
CX 2019: NICE AAA guidelines under the spotlight
The publication of the draft aortic guidelines by the National Institute for Health and Care Excellence (NICE) in May 2018 raised quite a stir. However, the story is not over. In a CX Special [...]
CX 2019: Vascular EDUCATION as it should be
CX is Europe’s largest and longest-running vascular symposium and delivers vascular EDUCATION as it should be CX raises CONTROVERSIES, CHALLENGES the evidence to reach CONSENSUS in a three yearly cycle after discussion involving a world-class faculty and expert audience. [...]
CX 2019: The last word on the paclitaxel controversy
Since the publication of Katsanos et al's meta-analysis in the Journal of the American Heart Association (JAHA), the science and support for paclitaxel-releasing devices in the legs is an unfolding story. A CX 2019 [...]